Biofourmis is a rapidly growing, global digital health company filled with committed, passionate professionals who care about augmenting personalized care and empowering people with complex chronic conditions to live better and healthier lives. We are pioneering an entirely new category of medicine by developing clinically validated, software-based therapeutics to provide improved outcomes for patients, smarter engagement & tracking tools for clinicians, and cost-effective solutions for payers. We are collectively devoted to a single-minded idea: powering personally predictive care. Our dynamic growth has been marked by quadrupled headcount in the last 12 months via both expansion & acquisition, yielding a global footprint with offices in Boston, Singapore, Bangalore, and Zurich. We are backed by prominent international venture capital investment & have cultivated relationships with worldwide healthcare stakeholders over the last 5 years.

Biofourmis is a rapidly growing, global digital health company filled with committed, passionate professionals who care about augmenting personalized care and empowering people with complex chronic conditions to live better and healthier lives. We are pioneering an entirely new category of medicine by developing clinically validated, software-based therapeutics to provide improved outcomes for patients, smarter engagement & tracking tools for clinicians, and cost-effective solutions for payers. We are collectively devoted to a single-minded idea: powering personally predictive care. Our dynamic growth has been marked by quadrupled headcount in the last 12 months via both expansion & acquisition, yielding a global footprint with offices in Boston, Singapore, Bangalore, and Zurich. We are backed by prominent international venture capital investment & have cultivated relationships with worldwide healthcare stakeholders over the last 5 years.

Biofourmis, a Boston-based global leader in virtual care and digital medicine, has announced its engagement with Wise Health System to launch a continuum-wide care-at-home initiative. Wise Health System is a four-hospital, integrated care network in the Dallas-Fort Worth metropolitan area. Wise Health System will launch the effort with a home hospital program leveraging Biofourmis' Hospital@Home end-to-end solution that combines artificial intelligence (AI)-based remote patient monitoring technology and clinical support services. Wise Health System has nearly 200 beds across its four-hospital campus, with over 200 physicians and more than 2,000 employees. The health system is launching a hospital at home program with Biofourmis as part of its progressive healthcare delivery philosophy, to enable participation in the Centers for Medicare and Medicaid Services' (CMS') Acute Hospital Care at Home program, for which it has already earned a waiver.

Remote patient monitoring company Biofourmis announced a $300 million Series D round this morning, a critical investment as the firm looks to products that not only identify when patients are likely to deteriorate, but can help manage their care. The company says that 20 hospitals have signed on to use its care at home services -- which includes monitoring devices and an app -- to help prevent costly ER care and readmissions. Next up: using patient data to drive treatment decisions, like titrating drug doses. Biofourmis has a pivotal trial under way for its BiovitalsHF software -- but even if results are positive, it faces hurdles in patient and provider acceptance. "That's going to be the linchpin, is if the patient trusts it enough to say, 'I'm not seeing my doctor every week, but I have to increase my dose every week,'" said cardiologist Ritu Thamman.

You're reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter delivered in your inbox every Tuesday and Thursday. Remote patient monitoring company Biofourmis announced a $300 million Series D round this morning, a critical investment as the firm looks to products that not only identify when patients are likely to deteriorate, but can help manage their care. The company says that 20 hospitals have signed on to use its care at home services -- which includes monitoring devices and an app -- to help prevent costly ER care and readmissions. Next up: using patient data to drive treatment decisions, like titrating drug doses.

Biofourmis, a startup developing digital therapeutics and artificial intelligence to remotely monitor patients, said its valuation hit $1.3 billion after raising a $300 million Series D funding round led by General Atlantic. The Boston-based company said CVS Health joined the round, along with existing investors, and also announced Omar Ishrak, chairperson of Intel and former CEO of Medtronic, will chair its board. Biofourmis had previously raised a $100 million round in September 2020 led by SoftBank Investment Advisers at an undisclosed valuation. This Series D round brings the company's total funding to $445 million. Originally based in Singapore, Biofourmis moved its headquarters to the United States in 2019.

It's probably no surprise that money is pouring into life sciences and healthcare startups during the biggest medical crisis in a century. CB Insights reported that global healthcare funding hit a new record $31.6 billion in this first quarter of 2021. It's also no shock that the two biggest trends – artificial intelligence and telehealth – also reaped record amounts of private cash. AI healthcare startups raised nearly $2.5 billion, while telehealth companies did even better by netting $4.2 billion in equity funding. That's the third consecutive quarter to hit record highs in both sectors dating back to Q3'20.

Suki, a startup that makes an AI-powered voice assistant for doctors, received two pieces of news from major clients less than three weeks ago. The first was that they'd need the product to accommodate telemedicine visits. The second was that they'd need autofilled clinical notes to quickly process patients who test positive for COVID-19 -- "Hey, Suki, write up a completed clinical note for COVID-19." The clients sent Suki their requirements and the data they'd gathered so far, and CEO Punit Soni called a meeting with his COO, head of customer success, product lead, sales lead and marketing lead. The meeting lasted 20 minutes.

Biofourmis, a fast-growing global leader in digital therapeutics, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its machine-learning and artificial intelligence (AI)-powered Biovitals Analytics Engine as a medical device for ambulatory physiological monitoring. This regulatory approval of the Biovitals Analytics Engine is part of FDA's growing recognition of machine-learning and AI in the Software as a Medical Device category. "This milestone approval is foundational to the Biovitals ecosystem, which includes not only our most advanced solution, BiovitalsHF for heart failure--but also our range of solutions across therapeutic areas, such as pain, oncology, sleep disorders and others in development," said Kuldeep Singh Rajput, CEO and founder of Biofourmis. "Receiving this important regulatory approval will only accelerate the development and commercialization of these innovative digital therapeutic solutions." This FDA approval is the second market authorization for Biofourmis, having earned the agency's approval in May 2019 for its Biovitals RhythmAnalytics platform, which is cloud-based software for automated interpretation of more than 15 types of cardiac arrhythmias.